Giants shortstop Willy Adames receives PRP treatment after UCL tear, targets short rest-and-rehab window

The Giants’ infield picture took a hit with news that shortstop Willy Adames was diagnosed with a torn UCL in his non-throwing elbow earlier this week. According to Susan Slusser of the San Francisco Chronicle, Adames instead received a platelet-rich plasma injection on Thursday, and will pursue a rest-and-rehab approach rather than immediate surgery.

The decision to treat the elbow conservatively is aimed at shortening the timetable for baseball activity. As reported in Giants notes, Adames’ projected rehab window is roughly three to four weeks, giving San Francisco a narrow window to evaluate how quickly throwing and fielding mechanics can return. Even when UCL procedures avoid the usual surgical path, innings, range, and throw frequency tend to dictate the real pace of recovery.

From a roster standpoint, the timing matters because a short rehab plan still often requires careful ramp-up. A torn ligament in a non-throwing elbow does not automatically remove risk for a position player’s defensive work, particularly for a middle infielder whose actions rely on quick, repeated arm use. The Giants’ day-to-day decision-making will likely center on how Adames progresses in activities that resemble game throwing and how his comfort holds up under intensity.

Adames is also a stabilizing presence by role, with the shortstop position carrying both defensive demands and high-frequency touches. When a starter is sidelined, teams generally look to their most reliable infield alternatives for routine ground balls and double-play turns. For the Giants, that means shuffling at-bats and defensive assignments in a way that protects overall execution, especially during late-game leverage situations.

Giants notes also referenced other internal angles, including the club’s broader player development and bullpen context. While this report primarily spotlights Adames’ elbow timeline, bullpen usage is often affected in the background when position-player absences change game flow. More defensive instability can slightly extend innings, and lineup adjustments can influence how quickly pitchers face the next turn of hitters.

Even with a three-to-four-week projection, the recovery path is rarely linear. Any conservative UCL plan generally requires progressive increases in workload, and teams typically err on the side of caution if discomfort returns during throwing. For San Francisco, the key question will be whether Adames can reach a point where he can be deployed as a full-time shortstop without limitations.

What to watch next is straightforward: updates on Adames’ progression through baseball-related activity, and how the Giants structure infield depth while he is out. If his rehab advances on the earlier end of the estimate, he could become an important mid-stretch option. If not, San Francisco may need to rely more heavily on its next wave of alternatives and tighten game planning to keep late-inning execution steady.

For the Giants and their fans, the emphasis is on the practicality of the plan: a PRP injection followed by rest and rehabilitation is designed to keep the season moving without committing to immediate surgery. The coming weeks will show whether that approach can translate into effective play on the field, not just improved imaging or reduced symptoms.